Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

261. Bronchial thermoplasty for asthma

Bronchial thermoplasty for asthma Final Bronchial Thermoplasty for Asthma: Findings & Decision Page 1 of 3 Health Technology Clinical Committee Findings and Decision Topic: Bronchial Thermoplasty for Asthma Meeting Date: May 20, 2016 Final Adoption: July 8, 2016 Meeting materials and transcript are available on the HTA website: www.hca.wa.gov/hta/meetingmaterials/Forms/ExtMeetingMaterials.aspx Number and Coverage Topic: 20160520A – Bronchial Thermoplasty for Asthma HTCC Coverage Determination (...) : Bronchial thermoplasty for asthma is not a covered benefit. HTCC Reimbursement Determination: Limitations of Coverage: NA Non-Covered Indicators: NA Agency Contact Information: Agency Phone Number Labor and Industries 1-800-547-8367 Public Employees Health Plan 1-800-200-1004 Washington State Medicaid 1-800-562-3022 WA - Health Technology Assessment May 20, 2016 Final Bronchial Thermoplasty for Asthma: Findings & Decision Page 2 of 3 HTCC Coverage Vote and Formal Action: Committee Decision Based

2016 Washington Health Care Authority

263. Randomised controlled trial: Aerobic exercise training reduces bronchial hyper-responsiveness and serum pro-inflammatory cytokines in patients with asthma

Randomised controlled trial: Aerobic exercise training reduces bronchial hyper-responsiveness and serum pro-inflammatory cytokines in patients with asthma Aerobic exercise training reduces bronchial hyper-responsiveness and serum pro-inflammatory cytokines in patients with asthma | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) in patients with asthma Article Text Therapeutics/Prevention Randomised controlled trial Aerobic exercise training reduces bronchial hyper-responsiveness and serum pro-inflammatory cytokines in patients with asthma Stefano R del Giacco 1 , Vanessa Garcia-Larsen 2 Statistics from Altmetric.com Commentary on: França-Pinto A , Mendes FAR , de Carvalho-Pinto RM , et al . Aerobic training decreases bronchial hyper-responsiveness and systemic inflammation in patients with moderate or severe asthma: a randomised

2016 Evidence-Based Medicine

264. Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away?

Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,400 family physicians, family medicine residents and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary (...) care research. www.acfp.ca May 9, 2016 Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Clinical Question: Are 1-2 doses of dexamethasone as effective as the standard five day prednisone regimen for treatment of pediatric asthma exacerbations? Bottom-line: Treatment of pediatric asthma exacerbations with short-course dexamethasone (0.6 mg/kg x 1-2 doses) is a safe and effective alternative to traditional five day courses of prednisone. For every ~20

2016 Tools for Practice

265. Pills vs. Puffers: Leukotriene receptor antagonists for childhood asthma

Pills vs. Puffers: Leukotriene receptor antagonists for childhood asthma Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,000 family physicians, family medicine residents and medical students in Alberta. Established over fifty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research (...) . www.acfp.ca January 18, 2016 Pills vs. Puffers: Leukotriene receptor antagonists for childhood asthma Clinical Question: Are leukotriene receptor antagonists (LTRAs) effective in pediatric asthma? Bottom-line: Using leukotriene receptor antagonists instead of inhaled corticosteroids as monotherapy will lead to one more exacerbation in every 21 patients. As add-on to inhaled corticosteroids, leukotriene receptor antagonists are inferior to long acting beta-agonists (LABAs), and show similar outcomes

2016 Tools for Practice

266. Evaluation and Management of Asthma in the Elderly

2014;60:99–107. 6 Kannan JA, Bernstein DI, Bernstein CK, Ryan PH, Bernstein JA, Villareal MS, Smith AM, Lenz PH, Epstein TG. Signi?cant predictors of poor quality of life in older asthmatics. Ann Allergy Asthma Immunol 2015;115:198–204. 7 Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, Liu X. National surveillance of asthma: United States, 2001- 2010. Vital Health Stat 3 2012;35:1–58. 8 Tsai CL, Lee WY, Hanania NA, Camargo CA Jr. Age-related differences in clinical outcomes (...) Evaluation and Management of Asthma in the Elderly AMERICANTHORACICSOCIETY DOCUMENTS AnOf?cialAmericanThoracicSocietyWorkshopReport:Evaluation andManagementofAsthmaintheElderly Gwen S. Skloot, Paula J. Busse, Sidney S. Braman, Elizabeth J. Kovacs, Anne E. Dixon, Carlos A. Vaz Fragoso, Nicola Scichilone, Y. S. Prakash, Christina M. Pabelick, Sameer K. Mathur, Nicola A. Hanania, Wendy C. Moore, PeterG.Gibson,SusanZieman,andBetinaB.Ragless;onbehalfoftheATSadhocCommitteeonAsthmaintheElderly

2016 American Thoracic Society

267. Asthma, Diagnosis and Management of

Asthma, Diagnosis and Management of Asthma, Diagnosis and Management of | ICSI The MN Health Collaborative includes physicians and other representatives from major healthcare organizations working together to address major health topics affecting Minnesota communities today. ICSI has been developing evidence-based clinical practice guidelines to improve patient care since 1993. ICSI helps forward-focused Minnesota health organizations find ways to redefine and redesign systems and the market (...) . Together, we aim to improve care and reduce costs for our patients, families and communities. e Guidelines Asthma, Diagnosis and Management of Revision Date: December 2016 / Eleventh Edition Endorsement Summary The ICSI Diagnosis and Management of Asthma guideline work group endorsed 2016 Global Strategy for Asthma Management and Prevention Report with added qualifications/comments. This report addresses the diagnosis and management of asthma in the pediatric and adult population. The GINA website

2016 Institute for Clinical Systems Improvement

268. A repeated short educational intervention improves asthma control and quality of life Full Text available with Trip Pro

A repeated short educational intervention improves asthma control and quality of life We assessed the effectiveness of an asthma educational programme based on a repeated short intervention (AEP-RSI) to improve asthma control (symptom control and future risk) and quality of life. A total of 230 adults with mild-to-moderate persistent uncontrolled asthma participated in a 1-year cluster randomised controlled multicentre study. The AEP-RSI was given in four face-to-face sessions at 3-month (...) intervals, and included administration of a written personalised action plan and training on inhaler technique. Centres were randomised to the AEP-RSI (intervention) group or usual clinical practice group. Specialised centres using a standard educational programme were the gold standard group. A significant improvement in the Asthma Control Test score was observed in all three groups (p<0.001), but improvements were higher in the intervention and gold standard groups than in the usual clinical practice

2016 EvidenceUpdates Controlled trial quality: uncertain

269. Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value Based Price Benchmarks

Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value Based Price Benchmarks ©Institute for Clinical and Economic Review, 2016 Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value- Based Price Benchmarks Final Report March 14, 2016 Institute for Clinical and Economic Review ©Institute for Clinical and Economic Review, 2016 Page i Final Report (...) . Public and Representative Private Insurer Coverage Policies 59 Appendix D. Previous Systematic Reviews and Technology Assessments 63 Appendix E. Ongoing Studies 64 Appendix F. Comparative Clinical Effectiveness Supplemental Information 66 Appendix G. Comparative Value Supplemental Information 70 Appendix H. Conflict of Interest Disclosures 73 ©Institute for Clinical and Economic Review, 2016 Page iv Final Report - Mepolizumab List of Acronyms Used in this Report ACQ Asthma Control Questionnaire ACT

2016 California Technology Assessment Forum

270. Evaluation of Systemic Antioxidant Level and Oxidative Stress in Relation to Lifestyle and Disease Progression in Asthmatic Patients Full Text available with Trip Pro

Evaluation of Systemic Antioxidant Level and Oxidative Stress in Relation to Lifestyle and Disease Progression in Asthmatic Patients Asthma is a chronic disorder of the airways. Oxidative stress is an important part of asthma pathogenesis. It plays a crucial role in exacerbating the disease, as well as an important consequence of airways inflammation.The present study was undertaken to investigate the lipid peroxidation and catalase activity in serum and antioxidant level in plasma of asthmatic (...) patients and their association with lifestyle and severity of the disease.A total of 210 subjects, 120 asthmatics and 90 healthy controls matched in respect to age, sex, lifestyle and socioeconomic status, were chosen randomly for the present study. The samples were analyzed for MDA concentration and catalase activity in serum and ferric reducing ability of plasma (FRAP). Statistical analysis was done using unpaired Student's t-test, ANOVA with Duncan post hoc test and Pearson coefficient

2015 Journal of medical biochemistry

271. Asthma and chronic obstructive pulmonary disease overlap syndrome: An update Full Text available with Trip Pro

Asthma and chronic obstructive pulmonary disease overlap syndrome: An update 27847903 2019 01 28 2450-131X 3 4 2015 Oct-Dec Journal of translational internal medicine J Transl Int Med Asthma and chronic obstructive pulmonary disease overlap syndrome: An update. 144-146 Lu Ming M Department of Respiratory Medicine, Peking University Third Hospital, Beijing 100191, China. Yao Wan-Zhen WZ Department of Respiratory Medicine, Peking University Third Hospital, Beijing 100191, China. eng Journal

2015 Journal of translational internal medicine

272. Environmental Microbial Exposure and Protection against Asthma. Full Text available with Trip Pro

Environmental Microbial Exposure and Protection against Asthma. 26699175 2015 12 31 2016 11 26 1533-4406 373 26 2015 Dec 24 The New England journal of medicine N. Engl. J. Med. Environmental Microbial Exposure and Protection against Asthma. 2576-8 10.1056/NEJMcibr1511291 Holt Patrick G PG Sly Peter D PD eng Journal Article United States N Engl J Med 0255562 0028-4793 0 DNA-Binding Proteins 0 Dust 0 Intracellular Signaling Peptides and Proteins 0 Lipopolysaccharides 0 Nuclear Proteins EC (...) 3.4.19.12 TNFAIP3 protein, human EC 3.4.19.12 Tumor Necrosis Factor alpha-Induced Protein 3 AIM IM Animals Asthma immunology prevention & control DNA-Binding Proteins biosynthesis Dust immunology Environmental Exposure Humans Intracellular Signaling Peptides and Proteins biosynthesis Lipopolysaccharides immunology Mice Nuclear Proteins biosynthesis Pyroglyphidae immunology Tumor Necrosis Factor alpha-Induced Protein 3 2015 12 25 6 0 2015 12 25 6 0 2016 1 1 6 0 ppublish 26699175 10.1056/NEJMcibr1511291

2015 NEJM

273. Airway reactivity and sphingolipids—implications for childhood asthma Full Text available with Trip Pro

Airway reactivity and sphingolipids—implications for childhood asthma Asthma is a clinically heterogeneous disorder, whose onset and progression results from a complex interplay between genetic susceptibility, allergens, and viral triggers. Sphingolipids and altered sphingolipid metabolism have emerged as potential key contributors to the pathogenesis of asthma. Orosomucoid-like 3 gene (ORMDL3) and the asthma susceptibility locus 17q21 have been strongly and reproducibly linked to childhood (...) asthma, but how this gene is functionally linked to asthma is incompletely understood. ORMDL proteins play an integral role in sphingolipid homeostasis and synthesis, and asthma-associated ORMDL3 polymorphisms have been associated with early viral respiratory infections and increased risk of asthma. ORMDL proteins act as inhibitors of serine palmitoyl-CoA transferase (SPT), the rate-limiting enzyme for de novo sphingolipid synthesis, and decreased sphingolipid synthesis through SPT increases airway

2015 Molecular and cellular pediatrics

274. The Impact of Bisphenol A and Phthalates on Allergy, Asthma, and Immune Function: A Review of Latest Findings Full Text available with Trip Pro

The Impact of Bisphenol A and Phthalates on Allergy, Asthma, and Immune Function: A Review of Latest Findings In recent years, the impact of environmental exposure to chemicals and their immunological effects, including the development of allergy, has been a topic of great interest. Epidemiologic studies indicate that exposure to endocrine-disrupting chemicals produced in high volumes, including bisphenol A (BPA) and phthalates, is ubiquitous. The links between their exposure (...) and the development of allergy, asthma, and immune dysfunction have been studied in vitro, in vivo, and through human cohort studies. The purpose of this review is to examine the current body of research and to highlight deficits and strengths of current findings. Emerging science indicates that deleterious immunologic changes, including increased propensity to develop wheeze, allergy, and asthma after dietary and inhalation exposure to these chemicals, may be occurring.

2015 Current environmental health reports

275. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations Full Text available with Trip Pro

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations Short-term targeted treatment can potentially prevent fall asthma exacerbations while limiting therapy exposure.We sought to compare (1) omalizumab with placebo and (2) omalizumab with an inhaled corticosteroid (ICS) boost with regard to fall exacerbation rates when initiated 4 to 6 weeks before return to school.A 3-arm, randomized, double-blind, double placebo-controlled (...) , multicenter clinical trial was conducted among inner-city asthmatic children aged 6 to 17 years with 1 or more recent exacerbations (clincaltrials.gov #NCT01430403). Guidelines-based therapy was continued over a 4- to 9-month run-in phase and a 4-month intervention phase. In a subset the effects of omalizumab on IFN-α responses to rhinovirus in PBMCs were examined.Before the falls of 2012 and 2013, 727 children were enrolled, 513 were randomized, and 478 were analyzed. The fall exacerbation rate

2015 EvidenceUpdates Controlled trial quality: predicted high

276. [Omalizumab for the management of asthma]

[Omalizumab for the management of asthma] Omalizumab para el tratamiento del asma [Omalizumab for the management of asthma] Omalizumab para el tratamiento del asma [Omalizumab for the management of asthma] Ruano Gándara R, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Ruano Gándara R, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A. Omalizumab para el tratamiento del asma. [Omalizumab for the management of asthma] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 440. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related aspects regarding omalizumab in the management

2015 Health Technology Assessment (HTA) Database.

277. A randomized, controlled, crossover study in patients with mild and moderate asthma undergoing treatment with traditional Chinese acupuncture. Full Text available with Trip Pro

A randomized, controlled, crossover study in patients with mild and moderate asthma undergoing treatment with traditional Chinese acupuncture. This study sought to verify the effects of acupuncture as an adjuvant treatment for the control of asthma.This was a randomized, controlled, crossover trial conducted at the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. A total of 74 patients with mild/moderate, persistent asthma were randomized into two therapeutic groups (...) , induced sputum cell count, exhaled nitric oxide (NO) and with the Short Form 36 (SF-36) and Questionnaire on Quality of Life-Asthma (QQLA) questionnaires. Daily peak flow and symptom diaries were registered. The level of significance adopted was 5% (α=0.05).In Group B, after real acupuncture, there was a decrease in eosinophils (p=0.035) and neutrophils (p=0.047), an increase in macrophages (p=0.001) and an improvement in peak flow (p=0.01). After sham acupuncture treatment, patients experienced less

2015 Clinics (São Paulo, Brazil) Controlled trial quality: uncertain

278. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. (Abstract)

Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis.

2015 Annals of Internal Medicine

279. Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. Full Text available with Trip Pro

Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. The efficacy and safety of long-acting β-agonists (LABAs) have been questioned. Black populations may be disproportionately affected by LABA risks.To compare the effectiveness and safety of tiotropium vs LABAs, when used with inhaled corticosteroids (ICS) in black adults with asthma and to determine whether allelic variation at the Arg16Gly locus (...) of the β2-adrenergic receptor (ADRB2) geneis associated with treatment response.A multisite (n = 20), open-label, parallel-group, pragmatic randomized clinical trial conducted from March 2011 through July 2013, enrolling black adults with moderate to severe asthma in the United States.Patients eligible for, or receiving, step 3 or step 4 combination therapy per National Heart, Lung, and Blood Institute guidelines, received ICS plus either once-daily tiotropium (n = 532) or twice-daily LABAs (n = 538

2015 JAMA Controlled trial quality: predicted high

280. Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society position paper

Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society position paper Asthma often starts before six years of age. However, there remains uncertainty as to when and how a preschool-age child with symptoms suggestive of asthma can be diagnosed with this condition. This delays treatment and contributes to both short- and long-term morbidity. Members of the Canadian Thoracic Society Asthma Clinical Assembly partnered with the Canadian (...) Paediatric Society to develop a joint working group with the mandate to develop a position paper on the diagnosis and management of asthma in preschoolers. In the absence of lung function tests, the diagnosis of asthma should be considered in children one to five years of age with frequent (≥8 days/month) asthma-like symptoms or recurrent (≥2) exacerbations (episodes with asthma-like signs). The diagnosis requires the objective document of signs or convincing parent-reported symptoms of airflow

2015 Canadian Paediatric Society